Literature DB >> 20385114

Selected performance characteristics of the Roche Elecsys testosterone II assay on the Modular analytics E 170 analyzer.

William E Owen1, Mindy L Rawlins, William L Roberts.   

Abstract

BACKGROUND: Serum testosterone measurements have utility in diagnosis of clinical conditions characterized by both increased and decreased testosterone concentrations. Studies have indicated that testosterone immunoassays may give inaccurate results for women and children. We evaluated the performance of a second generation testosterone immunoassay from Roche Diagnostics.
METHODS: Testo II performed on a Modular Analytics E 170 analyzer is an automated random access electrochemiluminometric assay. We evaluated limit of blank (LoB), imprecision, linearity, interference, and method comparison with liquid chromatography-tandem mass spectrometry assay (LC-MS/MS). Method comparison included the current generation Roche testosterone assay (Testo I) and the Access 2 testosterone chemiluminometric assay (Beckman Coulter). Results for men and women were analyzed for analytic concordance. The relative % differences of immunoassay compared to LC-MS/MS results were evaluated.
RESULTS: The LoB was 0.07nmol/l. Total imprecision was <6%. The assay was linear from 0.2 to 46.6nmol/l. Negative interference was observed for lipemia at concentrations >22.5g/l. Analytic concordance showed improved specificity for women. Comparison of results to LC-MS/MS indicated comparable performance with other immunoassays for men and improved performance for women, boys, and girls with mean differences of 0.5%, -0.7%, and 24.4%, respectively.
CONCLUSIONS: The Roche Testo II assay demonstrated excellent precision. Comparison to 2 other automated immunoassays showed comparable performance for men and improved performance for women and children. However, challenges still exist for quantifying testosterone concentrations <10.4nmol/l for men and <1.7nmol/l for women and children by immunoassay. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20385114     DOI: 10.1016/j.cca.2010.03.041

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Comparison of four clinically validated testosterone LC-MS/MS assays: Harmonization is an attainable goal.

Authors:  Deborah French; Julia Drees; Judith A Stone; Daniel T Holmes; J Grace van der Gugten
Journal:  Clin Mass Spectrom       Date:  2018-12-01

2.  High C-reactive protein is associated with increased risk of biochemical hypogonadism: a population-based cohort study.

Authors:  Amar Osmancevic; Kristin Ottarsdottir; Margareta Hellgren; Ulf Lindblad; Bledar Daka
Journal:  Endocr Connect       Date:  2022-06-24       Impact factor: 3.221

3.  Head-To-Head Assessment of Diagnostic Performance of Testosterone Immunoassays in Patients With Polycystic Ovary Syndrome.

Authors:  Andreas N Schüring; Stefan Nolte; Manfred Fobker; Frank Kannenberg; Jerzy-Roch Nofer
Journal:  J Clin Lab Anal       Date:  2015-10-26       Impact factor: 2.352

4.  Discordance between testosterone measurement methods in castrated prostate cancer patients.

Authors:  Mélanie Rouleau; Francis Lemire; Michel Déry; Benoît Thériault; Gabriel Dubois; Yves Fradet; Paul Toren; Chantal Guillemette; Louis Lacombe; Laurence Klotz; Fred Saad; Dominique Guérette; Frédéric Pouliot
Journal:  Endocr Connect       Date:  2019-02       Impact factor: 3.335

5.  Features of Neutrophils From Atopic and Non-Atopic Elite Endurance Runners.

Authors:  Raquel Freitas Zambonatto; Renata Nakata Teixeira; Sarah de Oliveira Poma; Eliane Borges da Silva; Mariana Mendes de Almeida; Gerson Dos Santos Leite; Cesar Miguel Momesso Dos Santos; Heloisa Helena de Oliveira Alves; Renata Gorjão; Tania Cristina Pithon-Curi; Celso R F Carvalho; Rui Curi; Adriana Cristina Levada-Pires
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.